Pharmaceutical core-shell composite powder and processes for making the same

Patent metadata

Field	Value
Publication number	US-9801820-B2
Application number	US-201314441970-A
Country	US
Kind code	B2
Filing date	Nov 8, 2013
Priority date	Nov 12, 2012
Publication date	Oct 31, 2017
Grant date	Oct 31, 2017

Abstract

A composite particle including a core with at least one carrier material; a fluidizing material layer on the surface of the core; and an outer layer comprising nanoparticles of an ingestible material distributed in at least one matrix-forming material. A process of making the composite particles includes the steps of dry coating carrier particles with a fluidizing material; preparing a suspension of nanoparticles of an ingestible material distributed in a matrix-forming material; and fluid bed coating the carrier particles with the suspension. The process and products provide quick dissolving composite particles which can be used for delivery of poorly water soluble ingestible materials in suitable dosage forms. The process of the invention reduces or prevents particle agglomeration during fabrication of the composite particles to enable delivery and quick redispersion of nanoparticles of the ingestible material from a dosage form.

First claim

What is claimed is:

1. A composite particle comprising:
a core, wherein the core is a particle having median particle size in a range of from about 20 μM to about 200 μM and
an outer layer comprising nanoparticles of an ingestible material and at least one matrix-forming material,
a fluidizing material layer located between the core and the outer layer, wherein the fluidizing material comprises nanoparticles, and
the ingestible material comprises at least one active pharmaceutical ingredient.

2. The composite particle of claim 1 , wherein the core comprises a material selected from starch, lactose, sucrose, cellulose, cellulose ethers and mixtures thereof.

3. The composite particle of claim 1 , wherein the fluidizing material comprises nanoparticles of a material selected from silica, alumina, titania, carbon black, aluminum calcium silicate, calcium silicate, magnesium silicate, potassium silicate, sodium silicate, sodium aluminosilicate, sodium calcium aluminosilicate, tricalcium silicate, silica aerogel, talc, iron oxide, other metal oxides and mixtures thereof.

4. The composite particle of claim 1 , wherein the fluidizing material has a dispersive surface energy of less than 60 mJ/m 2 and a median particle size of 5 nm to 100 nm.

5. The composite particle of claim 4 , wherein the fluidizing material comprises silica nanoparticles.

6. The composite particle of claim 1 , wherein the ingestible material comprises said at least one active pharmaceutical ingredient in range 0.01 to 50 wt %.

7. The composite particle of claim 6 , wherein the ingestible material particles have a size in the range of from about 10 nm to about 1000 nm.

8. The composite particle of claim 7 , wherein the ingestible material particles have a size in the range of from about 10 nm to about 200 nm.

9. The composite particle of claim 1 , wherein the matrix-forming material comprises at least one polymer.

10. The composite particle of claim 9 , wherein at least one polymer is selected from the group consisting of hydroxypropylcellulose, hydroxypropyl methylcellulose, poly(vinyl alcohol), poly(vinyl pyrrolidone, ammonio methacrylate copolymers, ethylcellulose, hydroxyl methyl celluolose, hydroxyethyl cellulose, methyl cellulose, carboxymethyl cellulose sodium salt, gum acacia and combinations thereof.

11. The composite particle of claim 10 , wherein at least one surfactant is selected from the group consisting of sodium dodecyl sulfate, dioctylsulfosuccinate, ethylene oxide/propylene oxide copolymers, cetyltrimethylammonium bromide, polyethylene sorbitol esters, sodium alginate, lecithin, sodium lauryl sulfate, monooleate, monolaurate, monostearate, stearylic alcohol, cetostearylic alcohol, tyloxapol, polyethoxylated castor oil, and mixtures thereof.

12. A process for preparing a composite particle, comprising the steps of:
preparing a suspension of nanoparticles of an ingestible material and at least one matrix-forming material; and
fluid bed coating the suspension onto carrier particles having a median particle size in a range of from about 20 μM to about 200 μM, and
a step of dry coating the carrier material with a fluidizing material prior to the fluid bed coating step, and
wherein the ingestible material comprises at least one active pharmaceutical ingredient.

13. The process of claim 12 , wherein the carrier particles comprise a material selected from starch, lactose, sucrose, cellulose, cellulose derivatives and mixtures thereof.

14. The process of claim 12 , wherein the nanoparticles have a median particle size in the range of from 5 nm to 100 nm.

15. The process of claim 12 , wherein the nanoparticle material is selected from the group consisting of silica, alumina, titania, carbon black, aluminum calcium silicate, calcium silicate, magnesium silicate, potassium silicate, sodium silicate, sodium aluminosilicate, sodium calcium aluminosilicate, tricalcium silicate, silica aerogel, talc, iron oxide, other metal oxides and mixtures thereof.

16. The process of claim 12 , wherein the dry coating is performed for a time sufficient to achieve a surface area coverage of the carrier material of from 35% to about 100%.

17. The process of claim 16 , wherein the fluidizing material comprises from 0.1% to 10% of a total weight of the fluidizing material and carrier material.

18. The process of claim 12 , wherein the active pharmaceutical ingredient comprises from 5% w/v % to 50 w/v % of a total weight of the suspension.

19. The process of claim 12 , wherein the active pharmaceutical ingredient containing particles have a size in the range of from about 10 nm to about 1000 nm.

20. The process of claim 12 , wherein a solvent used in the suspension is selected from tertiary butyl alcohol (TBA), tetrahydrofuran (THF), dimethyl sulfoxide (DMSO), dichloromethane, dimethyl formamide (DMF), methanol and mixtures thereof.

21. The process of claim 12 , wherein a solvent used in the suspension comprises water.

22. The process of claim 21 , wherein the suspension comprises at least one matrix-forming material and a surfactant.

23. The process of claim 12 , wherein the at least one matrix-forming material comprises a polymer.

24. The process of claim 23 , wherein the polymer is selected from the group consisting of hydroxypropylcellulose, hydroxypropyl methylcellulose, poly(vinyl alcohol), poly(vinyl pyrrolidone), poly(vinyl pyrrolidone)-K360, poly(vinyl pyrrolidone)-K30, ammonio methacrylate copolymer, ethylcellulose and combinations thereof.

25. The process of claim 23 , wherein the suspension further comprises a non-ionic surfactant.

26. The process of claim 23 , wherein the surfactant is selected from the group consisting of sodium dodecyl sulfate, dioctylsulfosuccinate, poloxamer 188, cetyltrimethylammonium bromide, poloxamer 407, polyethylene sorbitol ester, sodium alginate.

27. The process of claim 14 , wherein the at least one matrix-forming material comprises from 5 w/v % to 50 w/ % of the nanosuspension.

28. The process of claim 12 , wherein the fluid bed coating step uses a fluidizing velocity in a range of from 1 cm/s to 10 cm/s.

29. The process of claim 12 , wherein the fluid bed coating step uses a fluidizing flow rate in a range of from 0.1 cfm to 5 cfm.

30. The process of claim 12 , wherein the fluid bed coating step uses an atomization pressure in a range of from 5 psig to 35 psig to atomize the suspension.

Assignees

• New Jersey Inst Technology

Inventors

• To Daniel
• Dave Rajesh
• Knieke Catharina
• Bilgili Ecevit A
• Azad Mohammed A

Classifications

• A61K9/5078

  with drug-free core · CPC title

• A61K9/1694

  resulting in granules or microspheres of the matrix type containing more than 5% of excipient · CPC title

• A61K9/5089

  Processes · CPC title

• B05D1/22

  using fluidised-bed technique (fluidised-bed technique in general B01J8/24) · CPC title

• A61K9/14

  Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)} · CPC title